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Summary. Most haemophiliacs treated with non-virally-
inactivated clotting factor concentrates have been infected
with hepatitis C virus (HCV). We have studied the natural
history of chronic HCV infection by following all 138 HCV-
positive patients from our centre for periods of up to 28
years. As well äs the clinical and biochemical character-
istics, we studied 116 liver samples from 63 patients
obtained at elective biopsy (M = 103) or autopsy (n = 13).
36 (26%) of the patients were HIV positive, and three were
chronic carriers of hepatitis B. Evidence of previous
exposure to hepatitis A and B was found in 37-2% and
48-1% respectively. Raised transaminase levels were found
in 82-6% of patients. 11 of 15 patients with normal
transaminases tested by PCR for HCV RNA were positive,
indicating that most patients, even in this group, have
chronic hepatitis C infection. Cirrhosis was diagnosed by
liver histology in 19 patients, and nine patients developed
liver failure. The incidence of cirrhosis rose rapidly 15
years after HCV infection to 15-6 per 1000 person-years.
Multivariate analysis showed that HIV Status, length of
time since HCV infection and age at HCV infection were
independently associated with both the development of
cirrhosis and liver failure. Two patients developed hepato-
cellular carcinoma: one of these was exposed only to a
single batch of FVIII concentrate 11 years earlier. Chronic
hepatitis C is increasingly recognized äs a major cause for
morbidity and mortality in haemophiliacs, especially those
who are HIV positive and who were infected at an older
age.
Keywords: hepatitis C, HCV, natural history, haemophilia,
liver disease.
For more than 20 years it has been known that some
haemophiliacs treated for the flrst time with clotting factor
concentrates developed jaundice with biochemical evidence
of hepatitis (Kasper & Kipnis, 1972). Two studies from
England showed that the incidence of biochemical liver
abnormalities after flrst exposure was virtually 100%
(Fletcher et al, 1983; Kernoff et al, 1985). In the absence
of serological markers for hepatitis A or B the aetiologic
agent was called non-A, non-B (NANB). In 1989 the virus
responsible was cloned and named hepatitis C (Choo et al,
1989). Since 1985, clotting factor concentrates have
undergone viral inactivation, but almost all patients treated
prior to this have been infected with HCV (Makris et al,
1990).
Acute HCV hepatitis is often a trivial event; the clinical
importance of HCV infection lies in its propensity to progress
to histologically proven chronic liver disease. Prospective
studies in non-haemophiliacs with acute non-A, non-B
hepatitis reveal that approximately 50% of these subjects
will exhibit liver enzyme abnormalities characteristic of
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chronic hepatitis (Mattsson et al, 1988: Di Bisceglie et al,
1991; Seefei al, 1992). Histological examination of the liver
in patients with chronic hepatitis has revealed that 15-25%
of the patients have established cirrhosis (Mattsson et al,
1988; Di Bisceglie et al, 1991; Seefei al, 1992; Alter. 1989).
Despite the histological progression, the clinical features of
chronic liver disease are often unremarkable and the
eventual impact of chronic HCV on morbidity and mortality
remains to be established. The relatively benign nature of
chronic post-transfusion hepatitis was emphasized by Seef
et al (1992), who, in a prospective study, reported no
increased mortality among subjects with transfusion-
associated NANB hepatitis for up to 18 years after the
initial infection. A small but statistically significant
increase in the number of deaths related to liver disease
was, however, noted.
Recently two publications have reported the rapid
progression of HCV to end-stage liver failure in haemo-
philiacs, but in both reports this progression appeared to
occur almost exclusively in patients co-infected with the HIV
virus (Eyster et al, 1993; Telfer et al, 1994). The lack of
progression in the HIV-negative patients is in contrast to other
studies reporting liver failure deaths in recipients of blood
transfusion after intervals of 20 years.
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Here we report the natural history of HCV infecüon and
the progression of chronic HCV-related liver disease in a
cohort of haemophiliacs studied prospectively for periods of
up to 28 years since their flrst exposure to hepatitis C
through clotting factor concentrates.
PATIENTS AND METHOD
Patients. The cohort of 138 paüents in this study
constitutes all the known hepatitis C antibody positive
patients with hereditary haemorrhagic disorders treated in
Sheffield, U.K. 132 received non-virally inacüvated concen-
trates in the period 1968-85, four received heat-treated
products clearly implicated in HCV transmission (Makris et al,
1993) and two received only virally inactivated FVIII but prior
to 1985 received large quanüties of cryoprecipitate.
FoIIow-up. Patients with severe haemophilia (A and B)
were reviewed at least three times a year, whilst others
(including those with von Willebrand's disease) were
reviewed annually. HIV-positive patients were reviewed at
least 3-monthly. Recently all HCV antibody positive patients
have also been reviewed 4-monthly. Liver enzyme estima-
tion was performed at each visit.
Liver bwchemistry iests. Liver enzyme determinations
(Alanine [ALT] and aspartate [AST] aminotransferase)
were performed on each individual at every visit. The
pattern of liver enzyme abnormality was assessed on the last
three ALT estimations and was considered persistently
abnormal if all three estimates were abnormal and
intermittently abnormal if one or two were abnormal. In
patients treated with Interferon, the pattern of enzyme
abnormalities just prior to the commencement of therapy
was recorded.
Date ofHIV injection. For HIV-positive patients, the date of
HIV seroconversion was determined from stored sera and
taken to be the midpoint of the interval between the last
negative and flrst positive test. For patients for whom no
negative test was available, the midpoint of the interval
between 10 June 1981 (the date of the flrst HIV-positive test
in a Sheffield haemophiliac) and the date of the flrst positive
test was calculated. For patients who moved to Sheffield after
a diagnosis of HIV was made in another centre the date of
seroconversion was assumed to be 9 February 1983 (the
midpoint between the flrst and last seroconversion in
Sheffield haemophiliacs).
Date of HCV infection. This was assumed to be the date of
the patient's flrst exposure to clotting factor concentrate
prepared from pooled donations. In 25% of cases when this
was unknown the date of infection was taken to be l January
1972 (the date of widespread introduction of concentrates in
our centre); for persons born after this date it was taken to be
the date of their flrst birthday.
Histology. The criteria for performance of liver biopsy over
the period 1977-94 varied, and although most biopsies
were originally performed in patients with persistently
abnormal liver enzymes, later biopsies were also performed
in other patient groups. Liver biopsies were performed after
correction of the bleeding disorder äs previously described
(Makris et al, 1991). All liver histology was interpreted by a
single experienced histopathologist (J.C.E.U.) using Standard
criteria. Two patients who died of liver failure without
formal examination of liver tissue were assumed to have had
cirrhosis at the time of death. In three patients who
underwent liver transplantation, only liver histology of the
original liver is included.
Definition ofhepaüc decompensation. Hepatic decompensation
was deflned äs the presence of two of the following: ascites,
jaundice, prolonged prothrombin time or hepatic encephalo-
pathy. Ascites was detected clinically (this was marked in
each case), jaundice was deflned äs a bilirubin concentration
greater than twice the upper limit of normal, prothrombin
time Prolongation was accepted if it was more than 5 s
above the upper limit of normal (normal ränge 11-15 s).
Oesophageal varices were detected endoscopically or radio-
logically and hepatocellular carcinoma was conflrmed
histologically.
Virology iests. HCV was detected with a second-generation
ELISA test (Ortho Diagnostics). HBsAg, anti-HBc and anti-
HBs tests were performed using Standard techniques. All
positive HIV ELISA tests were conflrmed with the Western
blot technique. HCV RNA was detected with PCR äs
previously described (Preston et al 1995b).
Statistics. The risk of cirrhosis and liver failure over time
since infection with HCV was estimated by the Kaplan-Meier
life-table method. Briefly, with this method the probability
of event-free (cirrhosis or liver failure) survival over the
follow-up time is calculated, taking censoring into
account.
We calculated the incidence of cirrhosis by the patient-year
method. Here, we computed the time of follow-up for each
patient, i.e. the elapsed between the date of HCV infection and
either end of study, or cirrhosis, or death, whichever came
flrst. The overall incidence was then found by adding the total
patient-time of the cohort, and dividing the toted number of
cirrhotic events by the total patient-time. To investigate
whether the incidence varied with the time elapsed since
infection, we stratified the total follow-up time in periods since
infection: 0-4 years since HCV infection, 5-9 years, 10-14
years and 15+ years since HCV infection. By taking into
account in which period each cirrhotic event occurred, we
calculated incidence rates for each of these periods (e.g. if a
patient developed cirrhosis 8 years after HCV infection, he
would contribute 5 years to the first, and 3 years to the second
period, and his cirrhosis would be counted in the numerator of
the second period). Incidences for time since infection were
calculated for liver failure in the same way. A 95% confidence
interval (CI 95) was based on a Poisson distribution for the
outcome variable.
A Cox proportional hazards model was used to access the
effect of several other faclors on the risk of cirrhosis and liver
failure. This multivariate model allows for estimating the
effect of several risk factors, while controlling for possible
time trends in the baseline incidence which is allowed to
vary, and adjusted for other factors. For each factor the
model yields a hazard ratio, which can be viewed äs the ratio
of the incidence in the presence of that factor over the
incidence in the absence ofthat factor (which itself is allowed
to vary over time), adjusted for all other factors in the model.
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As covanates we used seventy of haemophiha (mild,
moderate, severe), HIV Status (negative positive) and age
at HCV mfection (m actual years and m classes 0-4 years,
5-9 years, 10-19 years, 20-29 years, 30-39 years, and
40+ years) A hazard ratio of l indicated an equal nsk m
the presence or absence of the factor of mterest, a hazard
ratio of > l mdicated an mcreased nsk associated with that
factor
RESULTS
Patient charactei istics
The cohort of 138 patients represents all the patients m
Sheffield with bleeding disorders diagnosed äs being HCV
positive up to January 1995 The mean age of the patients
was 3825 years with a ränge o f l l 1-872 years (Table I)
Total follow-up of the cohort was for 2596 7 person years
smce mfection with hepatitis C 127 of the patients were
male and m 71 the bleeding disorder was severe (FVIII/IX
< 0 02 m/ml) 121 patients had either haemophiha A or B,
10 patients suffered from von Willebrand's disease, five were
haemophiha carners, and two suffered from factor X deflciency
and were treated with non-virally mactivated prothrombin
complex concentrates
Table I. Chmcal charactenstics of the whole cohort of 138 HCV-
pobitive patients and of the 63 paüents on whom hver histology was
available
Age
Mediän
Range
Sex
Male
Female
Diagnosis
Haemophiha A
Haemophiha B
von Willebrand s disease
Other
Seventy of bleeding disorder
0 000-0 009 m/ml
s: 001 m/ml
002-0 05 m/ml
> 005 5 m/ml
ALT abnormahty
Persistent
Intermittent
Normal
Co-mfection
Anti-HIV positive
HBsAg positive
No dead
All patients
n = 138 (%)
3825
11 1-872
127(92)
11 (80)
97(703)
24 (174)
10 (72)
7(51)
18 (130)
71 (514)
15 (109)
50(362)
76(551)
39(283)
24(174)
36(261)
3 ( 2 2 )
26 (18 8)
Liver histology
patients
n = 63 (%)
44 1
18 3-780
61 (968)
2 ( 3 2 )
51 (81)
8 (12 7)
2 ( 3 2 )
2 ( 3 2 )
8 (12 7)
3 3 ( 5 2 3 )
6 ( 9 5 )
24(381)
44 (69 8)
14 (22 2)
5 ( 7 9 )
26 (41 3)
2 ( 3 2 )
20 (31 7)
Age ofHCV infectwn
Patients were mfected with HCV at a mean age of 21 66
(ränge 0 06-79 32 years) The followmg number of patients
were mfected in the different age groups 0-4 yeais, 26, 5-9
years, 20, 10-19 years 27, 20-29 years, 28, 30-39 years,
14, 40+ years, 23
Infection with othei vn uses
Thirty-six patients (26 1%) were HIV positive of whom 17
(47 2%) have died 35/94 (37 2%) patients were hepatitis A
IgG positive, mdicatmg past mfection with this virus Only
three patients are currently mfected with the hepatitis B
virus (i e HBsAg positive) but 65/135 (481%) had
evidence of previous exposure to this virus (anti-HBc
positive or anti-HBs positive in the unvaccinated patients)
Liver junclion tests
Seventy-seven of 138 (55 8%) patients had persistently
abnormal transammase levels, 37 (26 8%) had mtermit-
tently abnormal levels and in 24 (17 4%) all the last three
transammases were normal 15 patients from the group
with normal ALT were tested for HCV RNA usmg nested PCR
(Preston et al, 1995b) and 11 of these were found to be
positive, mdicatmg active viraemia rather than immunity
Histology was available on five members of this normal
transammase group, this showed cirrhosis m two, chronic
active hepatitis (CAH) m one and chronic persistant hepatitis
(CPH) m two
Liver bwpsies
Histology was available from 63 cohort patients Patients
had one to five hver biopsies In 13 patients who died,
histology was obtamed either by füll (n = 8) or hmited
(n = 5) autopsy
All hver histology was abnormal All biopsies showed
chronic hepatitis with varymg seventy Usmg histopathologi-
cal Standard cntena and nomenclature at the üme of biopsy,
37/63 (58 7%) of initial biopsies showed chronic persistent
hepatitis and 23/63 (36 4%) showed chronic active hepatitis
or cirrhosis Most biopsies also exhibited features associated
with HCV infection, such äs steatosis, smusoidal Infiltration by
leucocytes and portal lymphocytic aggregates 29 patients
had more than one hver biopsy Cirrhosis was found in the
most recent hver biopsy of 19 patients and hver failure
occurred in nme patients Table II details the data from the
19 patients with cirrhosis
The mean time from HCV infection to the development of
cirrhosis was 1858 (ränge 3 02-26 65 years) For hver failure
the mean was 19 15 (ränge 7 81-28 05 years) Overall the
mcidence of cirrhosis was 7 54 per 1000 person-years
followmg HCV mfection but it mcreased markedly from 2 9
per 1000 person years m the first 5 years followmg infection to
156 per 1000 person-years after > 15 years followmg HCV
mfection had elapsed (Table III) No patient showed signs of
hver failure within 4 years of HCV mfection, but after this
period the number of patients developmg hver failure was fairly
constant at a mean mcidence of 3 47 per 1000 person-years
Fig l shows a Kaplan Meier plot for the development of
cirrhosis and hver failure from the time of HCV mfection 22
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Table II Chaiactenstics of paüents with hepdtic decompensation or cirrhosis
Patient
015
064
027
006
104
125
098
010
116
056
123
042
072
080
103
131
121
054
032
Diagnosis
Haemophiha B
Haemophihd A
Haemophiha A
Haemophiha A
Haemophihd A
Haemophiha A
Haemophilia A
Haemophiha A
von Willebiand s disease
Haemophiha A
Haemophiha A
Haemophiha A
Haemophihd A
Haemophiha A
Haemophiha B
Haemophiha A
Haemophiha A
Haemophüid A
Haemophihd A
Seventy
(m/ml)
005
003
007
009
007
001
001
0 10
0 18
001
0 10
001
001
0 16
001
001
001
001
001
Age at HCV
mfection
(yr)
654
63 9
570
552
480
480
46 6
41 8
344
342
29 8
26 8
25 7
24 7
23 0
174
5 8
3 6
14
Age at HIV
mfection
(yr)
NA
70 5
669
NA
NA
609
NA
NA
NA
38 3
NA
NA
373
NA
NA
290
16 5
14 7
12 6
Age dt biopsy
of cmhosis
(yi)
780
71 8
706
NA
51 0
55 1
53 5
448
384
NA
450
423
453
45 8
40 7
38 3
270
254
84
Age at hepatic
decompensation
(yr)
779
71 8
NA
33 7
58 7
NA
54 5
NA
NA
43 3
NA
NA
NA
NA
NA
366
NA
254
NA
Age at
outcome
(yr)
Dead 78 0
Dead 72 2
Dead 70 6
Dead 77 6
Transplant 63 2
Dead 65 1
Dead 551
Transplant s 7 7
Ahve 51 S
Dead 43 6
Ahve 519
Ahve 48 7
Dead 45 3
Ahve 52 6
Dead 415
Dead 383
Dead 2 8 7
fransplant 264
Ahve 24 3
years after HCV mfection at least 19% of cohort patients
developed cirrhosis and 9% developed hver failure
Hepatoceüulm cm cmoma
Two patients developed hepatocellular carcmoma (HCC)
The flrst patient was shown by hver biopsy to have had
cirrhosis 13 years pnor to the Identification of HCC As no
metastases were present he underwent hver transplantaüon
and is ahve and well 5 years later The second patient
received only a single batch of non-virally mactivated FVIII
concentrate He was HIV negative but presented 11 years
later with end-stage hver failure Limited autopsy confirmed
the presence of HCC
Tactors mfluencmq disease progression
Multivanate analysis usmg Cox s proportional hazards
model was used to analyse the effect of seventy of haemophdia
HIV Status and age at mfection with HCV on the development
of cirrhosis and hver failure This analysis allows for a change
in the basehne incidence over time i e the observed mcreasing
nsk after > 15 years In a model mcluding age (in years)
seventy of haemophiha (mild moderate severe) and HIV
mfection (positive or negative) seventy of haemophiha
appeared not to be associated with the risk of development of
either cirrhosis or hver failure (Table IV) Patients who were
HIV positive had a 3 9-fold mcreased incidence of hver
cirrhosis (CI 95 l 4-10 8) compared to those who remamed
HIV negative The risk of cirrhosis appeared to be higher for
those who were mfecled at an older age with an average of a
5% higher nsk for each year older a patient was when mfected
Because of the scarcity of data it was not possible to assess all
age classes m the multivanate model and so determine
whether this average is true over all age groups In the model
with only the age classes we did not find a steaddy mcreased
nsk with age at the time of mfection but a constant nsk was
found for those mfected before the age of 20 years and a
Table III The incidence and 95% confidence mtervals of cirrhosis
and hver failure after HCV mfeclion shown per 1000 person years
Cirrhosis
mfection (yr) Incidence
0-4
5-9
10-14
15+
All
2 91
755
3 74
15 56
752
Liver failure
CI95
025-848
2 31-15 81
032-1089
727-2695
446-11 36
Incidence
0
441
3 64
5 9
347
CI95
0 00-4 35
079-1099
031-1060
148-13 28
1 54-6 16
Proportion without disease
1 Οτ ' 1
0 8
8 10 12 14 16 18
Time since HCV mfection (yr)
22 24
Fig l Kaplan Meier analysis showing cumulative incidence of
cirrhosis (broken hne) and hver failure (solid hne) followmg HCV
mfection in the 138 cohort patients
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Table IV. Multivariate modelling results.
Cirrhosis äs endpomt
Hazards ratio Cl 95
Liver failure äs cndpoint
Hazards ratio CI 9 5
Univariate analysis
Seventy of haemophilia
Mild
Moderate
Severe
Grouped linear
HIV Status
Negative
Positive
Age at infection (yr)
0-4
5-9
10-19
20-29
30-39
40+
Grouped linear
Mulüvariate analysis
Severity of haemophilia
HIV Status
Age at infection
Model with age in years
Severity of haemophilia
HIV
Age at infection
1-0
0-76
0-77
0-88
1-0
2-36
1-0
0-50
0-36
2-23
1-94
5-42
1-64
0-80
3-88
1-80
0-85
3-92
1-05
0-16-3-67
0-29-2-04
0-54-1-44
0-96-5-81
0-045-5-51
0-032-3-93
0-43-11-49
0-27-13-82
1-15-25-56
1-21-2-22
0-46-1-41
1-40-10-76
1-28-2-54
0-48-1-53
1-42-10-85
1-03-1-08
1-0
1-82
0-75
0-85
1-0
2-10
1-0
204
0-83
4-18
2-43
0-96
4-21
1-08
0-30-10-97
0-17-3-4
0-42-1-73
0-56-7-82
1-27-3-60
0-37-1-83
0-94-18-55
1-36-4-32
0-41-2-21
0-96-18-41
1-04-1-13
higher increasing risk identifled for those infected after age 20
(although the numbers in each age group were too small to
allow formal tests of significance). In this univariate analysis,
the risk was highest for those who were 40 years and older
when infected: they had a 5-4-fold higher incidence of cirrhosis
than those who were 0-4 years old when infected (CI 95 1-2-
25-6).
The results for liver failure were essentially similar:
severity of haemophilia had no effect on the development
of liver failure, neither in univariate analysis nor when
adjusted for HIV infection and age at HIV infection, whereas
the risk was increased 4-2-fold for the HIV-positive patients
(CI 95 1-4-4-3) and also increased by age (hazards ratio
1.08, CI 95 1-04-1-13), i.e. an 8% higher risk for developing
liver failure during follow-up for each year older a patient
was at the time of HCV infection.
DISCUSSION
We found that 83-2% of patients had abnormal trans-
aminases consistent with the diagnosis of chronic HCV. This
flgure is similar to that reported by Cederbaum et al (1982)
from the U.S.A. (85%) and also by Telfer et al (1994) (83-5%).
Cederbaum et al (1982) used the same method of deflning
abnormal ALT äs we did (i.e. on the basis of the last three
levels), but äs it was carried out prior to the HCV Identification
the patients were not preselected on the basis of HCV
antibody. Telfer et al (1994) selected their patients in an
identical manner to ours but based their figures on the ALT
pattern over the last 5 years. It is unclear how many of the
patients with normal ALT have cleared the HCV virus and
are now immune. The literature suggests that HCV becomes
chronic in only 50% of non-haemophiliac patients, a figure
much lower than the > 80% seen in haemophiliacs. Our
data suggest that even patients with normal ALT can have
chronic HCV, äs shown by the fact that 1]/15 (73%) patients
tested were found to be viraemic; 2/5 of these patients had
cirrhosis on liver biopsy. We have no liver histology from the
small number of patients who have normal enzymes and are
HCV PCR negative, so it is not possible to conclude that any
haemophiliac has cleared the HCV virus.
Evidence of past infection with hepatitis A was found in
3 7-2% of our patients, a figure very similar to that found in the
general U.K. population, suggesling that this virus was not
transmitted to any significant degree by non-virally
inactivated concentrates. Despitc the fact that 48-1% of
patients have had infection with hepatitis B at some time,
only three (2-2%) patients remain HBsAg positive, a figure
similar to other U.K. series (Telfer et al, 1994); this
confirms the very minor role that chronic hepatitis B has
in the development of chronic liver disease in haemophi-
liacs. 26-1% of this cohort were HIV positive, a figure lower
© 1996 Blackwell Science Ltd, Bnüsh Journal o] Haematology 94: 746-752
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than the two recent series reporting accelerated liver disease
in HIV-positive haemophiliacs. In the Telfer cohort, 40-4% of
patients were co-infected with HIV/HCV (Telfer et al, 1994),
whereas Eyster et al (1994) found that 62-8% of the
patients were co-infected with both HIV and HCV. The
difference between our co-infection figures and those of
Telfer and Eyster are important in assessing the natural
history of the cohort äs a whole.
In our cohort, survival analysis has shown that after
22 years at least 19% of the patients have cirrhosis and 9%
liver failure, providing evidence that liver disease is now
becoming a major cause of morbidity and mortality in
haemophilia. The incidence of cirrhosis increases with
time after HCV infection to 15-56 per 1000 person-years,
15 years after infection. Within the time period of follow-up
of our cohort no significant increase in the incidence of liver
failure with time was seen. Our Interpretation of this is that
the risk of cirrhosis is present from early infection onwards,
but remains quite low, and fairly constant, until around 15
years post infection, after which the risk increases drama-
tically. The development of liver failure lags 5-10 years after
cirrhosis, so the increase is much less clear since follow-up is
not yet long enough. If we are correct, this flnding has
important implicatioiis for the haemophilia Community who
were infected with HCV around 20 years ago and would only
now be expected to Start presenting with liver failure in
significant numbers.
Co-infection with the HIV virus was the most important
factor contributing to the development of cirrhosis and liver
failure. This is consistent with the Undings reported by Eyster
et al (1993) in Pennsylvania and Telfer et al (1994) in
London. It is important to appreciate, however, that
significant HCV morbidity and mortality occurs in HIV-
negative patients; indeed in our cohort half of the patients
with documented cirrhosis or liver failure were HIV
negative. The possibility of more rapid progression of liver
disease in HIV co-infected patients was first raised by Martin
ei al (1989), who observed that progression of NANB
hepatitis to liver failure in three HIV-positive patients
occurred within 3 years of the hepatitis infection through
blood transfusion. It is unclear why liver disease progresses
more rapidly in HIV-positive patients. Patients with HIV
infection have higher circulating HCV RNA levels and it has
been suggested that concurrent opportunistic infections in
these patients could precipitate liver failure in an already
cirrhotic liver (Telfer et al, 1994). Similar accelerated liver
disease in immunocompromised patients has been observed
in patients with combined immunodeficiency who were
infected with HCV through contaminated intravenous
immunoglobulin (Bjoro et al, 1994) and in patients who
have had liver transplanls for HCV where the immuno-
suppression given to prevent graft rejection appears to
contribute to the accelerated HCV that invariably infects the
new liver (Villa et al, 1995).
We have idenüfied age äs an important variable in the rate
of progression of the liver disease. Both the age of the patient
at the time of infection and the time since HCV infecüon were
independently associated with disease progression. A similar
observation was reported in non-haemophiliacs by Yano et al
(1993) who performed serial liver biopsies in Japanese
patients who acquired their HCV through blood transfusion.
Although it is easy to see why the period of time since
infection is important in disease progression of a chronic
disease, it is more difficult to explain why the age at the time
of infection is important. A similar acceleration in disease
progression in older patients has already been reported for
HIV infection in haemophiliacs (Darby et al, 1990).
Two of our cohort patients developed hepatocellular
carcinoma. This complication of HCV in haemophiliacs
was first reported by Colombo et al (1991), who, in a
multicentre study, found HCC to be 30 times greater than
expected. Recently, a similar increase was reported from the
U.K. (Preston et al, 1995a). Since screening with hepatic
ultrasound and alpha fetoprotein estimation offers the
possibility of early HCC diagnosis and äs liver transplanta-
tion offers the possibility of 'eure' in those diagnosed early, it
should be considered in the follow-up of all HCV-positive
haemophiliacs.
Our study is strengthened by the long period of follow-up
and the large number of patients and liver biopsies
performed in this cohort. Any bias due to back-extrapolation
of the follow-up period, if present, will be small and will not
affect our conclusions: first we observed an increasing risk
with time since infection, which cannot be explained by
cirrhotic deaths occurring in the early years following
infection of patients who were never part of our cohort (there
were very few deaths from cirrhosis in haemophilia patients
in the U.K. before 1980); second, from the pathogenesis of
hepatitis and cirrhosis, an increasing risk over time is
plausible.
It is unlikely that many patients were infected with HCV
from unscreened blood, fresh frozen plasma and cryopreci-
pitate before the introduction of concentrates; the incidence
of confirmed HCV infections in blood donors of our region is
OO5% (V. James, personal communication).
The 19 patients found to have cirrhosis is likely to be a
great undcrestimate since some non-biopsied patients are
likely to have asymptomatic cirrhosis. Furthermore, patients
biopsied some years ago are likely to have progressed to
asymptomatic cirrhosis.
Although alcohol may accelerate progression of chronic
HCV-related liver disease, only 15-3% of our cohort admitted
to be drinking more than 20 units of alcohol per week, and
none of the biopsies contained sufficient Mallory's hyalin to
suggest that alcohol was a more likely cause for the liver
injury.
We conclude that most haemophiliacs treated with non-
virally inactivated concentrates have biochemical and
histological evidence for chronic hepatitis. Within 22 years
of infection at least 19% of patients have cirrhosis and 9%
have developed liver failure. In addition to an accelerating
effect of HIV on HCV-related liver disease, we have also
demonstrated that progression is influenced by increasing
age at the time and the interval since HCV infection. These
are the same factors that mitigate against Interferon
response and therefore in the context of chronic liver disease
in haemophilia there is an urgent need to explore new
therapeutic modalities.
© 1996 Blackwell Science Ltd, Briüsh Journal of Haematology 94: 746-752
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